Polycystic ovary syndrome
Conditions
Brief summary
Anthropometrics (weight), Androgenicity (hirsutism and testosterone), Metabolic (HOMA-IR), Gastrointestinal side-effects (nausea, vomiting, abdominal pain), Polycystic ovary morphology: AMH
Detailed description
Androgenicity: FAI, SHBG, DHEAS, androstenedione, free testosterone, acne and alopecia, Menstrual cyclicity (questionnaire where asking how long the two previous cycles were (days), Quality of life and weight stigma: anxiety, weight stigma, Metabolic: fasting glucose, fasting insulin, HbA1C, lipids, CRP, ALAT, GGT, OGTT, FLI, Matsuda Index, TyG index, Polycystic ovary morphology: ultrasound (follicle number per ovary, ovarian volume), Anthropometric (BMI, waist-hip-ratio, WC, BAI, body composition, bloodpressure, pulse)
Interventions
DRUGMETFORMIN
DRUGMETFORMIN HYDROCHLORIDE
Sponsors
HUS-yhtymae
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anthropometrics (weight), Androgenicity (hirsutism and testosterone), Metabolic (HOMA-IR), Gastrointestinal side-effects (nausea, vomiting, abdominal pain), Polycystic ovary morphology: AMH | — |
Secondary
| Measure | Time frame |
|---|---|
| Androgenicity: FAI, SHBG, DHEAS, androstenedione, free testosterone, acne and alopecia, Menstrual cyclicity (questionnaire where asking how long the two previous cycles were (days), Quality of life and weight stigma: anxiety, weight stigma, Metabolic: fasting glucose, fasting insulin, HbA1C, lipids, CRP, ALAT, GGT, OGTT, FLI, Matsuda Index, TyG index, Polycystic ovary morphology: ultrasound (follicle number per ovary, ovarian volume), Anthropometric (BMI, waist-hip-ratio, WC, BAI, body composition, bloodpressure, pulse) | — |
Countries
Finland
Outcome results
None listed